Navigation Links
Alexza Pharmaceuticals to Present at the Sixth Annual JMP Securities Healthcare Conference
Date:9/15/2011

MOUNTAIN VIEW, Calif., Sept. 15, 2011 /PRNewswire/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that the company will participate in the Sixth Annual JMP Securities Healthcare Conference, being held in New York, New York, September 27 - 28, 2011.  The Alexza corporate presentation will be Wednesday, September 28, 2011 at 10:30 am ET.  The presentation will be webcast live.

To access the presentation via the Web, please go to the Investor Relations tab at www.alexza.com or directly at http://wsw.com/webcast/jmp14/alxa/.  A replay of the webcast will be available approximately 24 hours after the live presentation and archived for 14 days.

About Alexza Pharmaceuticals, Inc.

Alexza is a pharmaceutical company focused on the research, development and commercialization of novel, proprietary products for the acute treatment of central nervous system conditions.  Alexza's technology, the Staccato® system, vaporizes unformulated drug to form a condensation aerosol that, when inhaled, allows for rapid systemic drug delivery through deep lung inhalation.  The drug is quickly absorbed through the lungs into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous administration, but with greater ease, patient comfort and convenience. (Click here to see an animation of how the Staccato system works.)

Adasuve™ (Staccato loxapine), Alexza's lead program, is being developed for the rapid treatment of agitation in adults with schizophrenia or bipolar disorder.  Alexza has completed and announced positive results from both of its Phase 3 clinical trials and initially submitted the ADASUVE NDA in December 2009.  In October 2010, the Company received a Complete Response Letter from the FDA regarding the application.  The Company completed an end-of-review meeting with the FDA in December 2010 and a Risk Evaluation and Mitigation Strategy (REMS) guidance meeting with the FDA in April 2011.  The ADASUVE NDA was resubmitted on August 4, 2011, and has a Prescription Drug User Fee Act (PDUFA) goal date of February 4, 2012.  The FDA has indicated that it will likely present the ADASUVE application to an Advisory Committee during the review period.  The Company also plans to file the ADASUVE Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) in the second half of 2011.

For more information about Alexza, the Staccato system technology or the Company's development programs, please visit www.alexza.com.

Safe Harbor Statement

The anticipated presentation will contain forward-looking statements that involve significant risks and uncertainties. Any statement describing the Company's expectations or beliefs is a forward-looking statement, as defined in the Private Securities Litigation Reform Act of 1995, and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of developing and commercializing drugs, including the adequacy of the Company's capital to support the Company's operations, the potential of the Company's ADASUVE NDA resubmission to adequately address the issues in the CRL, the timing of the FDA's review of the NDA, and the eventual prospects that ADASUVE will be approved for marketing. The Company's forward-looking statements also involve assumptions that, if they prove incorrect, would cause its results to differ materially from those expressed or implied by such forward-looking statements. These and other risks concerning Alexza's business are described in additional detail in the Company's Annual Report on Form 10-K for the year ended December 31, 2010, and the Company's other Periodic and Current Reports filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Alexza Announces Adasuve™ (Staccato® Loxapine) PDUFA Goal Date of February 4, 2012
2. Alexza Announces Resubmission of AZ-004 (Staccato® Loxapine) NDA
3. Alexza to Announce 2011 Second Quarter Financial Results on Monday, August 8, 2011
4. Alexza Reports 2011 First Quarter Financial Results and Provides Business Update
5. Alexza to Present at the MDB Bright Lights Conference 2011
6. Alexza Prices $16.1 Million Registered Direct Offering
7. Alexza Reports 2010 Fourth Quarter and Full Year Financial Results and Provides General Corporate Update
8. Alexza to Announce 2010 Year-End Financial Results on Tuesday, March 15, 2011
9. Alexza Pharmaceuticals Completes End-of-Review Meeting With FDA for AZ-004 (Staccato® Loxapine) NDA
10. Alexza Pharmaceuticals Provides Regulatory Update for AZ-004 (Staccato® Loxapine)
11. Alexza Pharmaceuticals Reports 2010 Third Quarter Financial Results and Provides Business Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/7/2017)...  Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation,s largest independent ... 30, 2017.  All comparisons, unless otherwise noted, are to the ... Second Quarter 2017 Highlights include: ... increase of 3.5% Total prescriptions dispensed of ... 7.5% versus 7.6% Gross profit per ...
(Date:8/4/2017)... , Aug. 4, 2017 The search ... shortly after a physician/patient consult has long been the ... was a notable focus of the largest meeting of ... according to healthcare market research firm Kalorama Information.  The ... testing (POCT) offerings or related supplies and software were ...
(Date:8/3/2017)... , Aug. 3, 2017  Opioid addiction and ... driving up healthcare costs and threatening outcomes, were problems ... supply and IVD industry that support them, met this ... market researcher said that drugs of abuse, procalcitonin and ... sessions at the organization,s 69th meeting in ...
Breaking Medicine Technology:
(Date:8/22/2017)... ... August 22, 2017 , ... ... to announce the addition of Zack Tisch as the firm’s new Consulting Services ... healthcare IT consulting firm’s national accounts, from assisting clients with initial vendor selection ...
(Date:8/22/2017)... , ... August 22, 2017 , ... ... (RCM) solutions, announced recently the availability of a new professional fee E/M leveling ... for their service to the healthcare industry. E/M coding is complex which supports ...
(Date:8/22/2017)... ... August 22, 2017 , ... Five Star Glass is new to the Texas market, ... replacement of auto glass for most makes and models, in Grand Prairie, TX, located in ... , They have been a family owned business for the past 40 years with 32 ...
(Date:8/22/2017)... (PRWEB) , ... August 22, 2017 , ... “Wilderness Voices”: ... of world travel. “Wilderness Voices” is the creation of published author, Martha McKown, ... Martha McKown was inspired as a very young child when her older sisters studied ...
(Date:8/22/2017)... ... 2017 , ... “Covert Awakening”: Walid’s spiritual journey from Islamic ... Hale, a consultant for the Intelligence Community. For more than ten years, ... East region. Julianne has written hundreds of reports for the US government ...
Breaking Medicine News(10 mins):